A new assay to assess steroid-hormone responsiveness in head and neck cancer

Nicholas J. Berg, H. Bryan Neel, Louis H. Weiland, Thomas C. Spelsberg

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

A new assay has been developed to predict the effectiveness of steroid-hormone therapy in various tumors. The Biopsy Nuclear Binding assay measures the amount of biologically activereceptorthatbindsbothsteroidhormoneandacceptor sites in the nucleus. This assay does not measure the entire receptor population, only those that arebiologically active; therefore, it should more accurately predict the response to steroid-hormone therapy. We applied this assay effectively in breast and endometrial carcinoma. Preliminary studies have shown that 40% of patients with head and neck squamous-cell carcinomas have biolo gically active (nuclear bound) pro gesterone receptors. If nuclear binding predicts a remission with hormonal therapy, then the quality of life of appropriately selected patients could greatly improve.

Original languageEnglish (US)
Pages (from-to)286-290
Number of pages5
JournalLaryngoscope
Volume97
Issue number3
DOIs
StatePublished - Mar 1987

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'A new assay to assess steroid-hormone responsiveness in head and neck cancer'. Together they form a unique fingerprint.

  • Cite this